Auryxia ferric citrate Updated Nov 7
Auryxia has no upcoming binary catalyst; its revenue trajectory is a steady decline driven by Teva's generic entry in March 2026. The next meaningful event for Akebia as a whole is the January 2027 expiration of Vafseo's TDAPA transitional add-on payment, which could pressure Vafseo pricing. Investors should watch Q4 2026 Auryxia revenue (expected in early March 2027) to gauge the pace of generic erosion.
- Auryxia remains FDA-approved for two indications (hyperphosphatemia in dialysis CKD, and iron deficiency anemia in non-dialysis CKD), providing a dual-label advantage over some phosphate binders.
- Despite generic pressure, Auryxia still generated $20 million in Q3 2026 revenue, contributing cash flow that helps fund Akebia's transition to its next-generation product Vafseo.
- Analyst consensus on AKBA remains bullish (10 analysts: 4 strong buy, 6 buy, 2 hold) with a mean price target of $3.92, implying roughly 820% upside from the current ~$0.40 share price.
- Teva launched a generic version of ferric citrate on March 11, 2026, directly competing on price and eroding Auryxia's market share rapidly.
- Auryxia Q3 2026 net revenue fell 53% year-over-year to $20.0 million (from $42.5 million), and the company expects further declines in 2026.
- Akebia swung to a $14.4 million net loss in Q3 2026 from a $0.5 million profit a year earlier, driven largely by Auryxia's decline.